Combining Osimertinib and Gedatolisib for Glioblastoma Treatment
Author Information
Author(s): de São José Vitória Santório, Vieira Bruno Marques, Neto Vivaldo Moura, Lima Lidia M.
Primary Institution: Universidade Federal do Rio de Janeiro
Hypothesis
Can the combination of Osimertinib and Gedatolisib provide a more effective treatment for glioblastoma than monotherapies?
Conclusion
The combination of Osimertinib and Gedatolisib shows synergistic effects that could lead to a new potential treatment for glioblastoma.
Supporting Evidence
- The combination of Osimertinib and Gedatolisib showed a significant reduction in cell viability in glioblastoma cell lines.
- Both drugs individually displayed cytotoxic effects, but their combination enhanced these effects.
- The study demonstrated that the drug combination led to increased apoptosis in glioblastoma cells.
- Cell migration was significantly reduced when both drugs were used together.
- The combination therapy resulted in G0/G1 cell cycle arrest in glioblastoma cells.
Takeaway
Researchers found that using two drugs together can work better to fight a type of brain cancer called glioblastoma than using just one drug.
Methodology
The study used in vitro phenotypic models with five human glioblastoma cell lines to test the effects of Osimertinib and Gedatolisib.
Limitations
The study was conducted in vitro, and results may not directly translate to in vivo effectiveness.
Participant Demographics
Human glioblastoma cell lines were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website